XTR006 not checked

Sinotau Pharmaceutical Group

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
5 active
5 in total · 4 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“all patients will receive one injection of \[18F\]XTR006, a PET radiopharmaceutical selective for NFTs. For the injection, subjects will receive a target dose of 4-6 mCi IV as a bolus injection. \[18F\]XTR006 injection will be followed by a 10 ml saline flush.”In the company’s words, NCT07115238 on ClinicalTrials.gov
Tested for
Alzheimer Disease, Neurofibrillary Tangle
Main trialPhase 3
“The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), and cognitively normal individuals. The main question it aims to answer is: • What is the sensitivity and specificity of XTR006 PET visual reading results compared to the truth standard across MCI, AD, and cognitively normal subjects? Participants will: * Receive XTR006 injection * Undergo PET/CT scanning”In the company’s words, NCT07115238 on ClinicalTrials.gov
Other names
Florquinitau

Other drugs for Alzheimer Disease

All 91 drugs for Alzheimer Disease

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 Dec 2025 Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
Phase 2Authorised not given Longitudinal multicenter head-to-head harmonization of tau PET tracers (HEAD Study)
Phase 3/4Authorised not given Cognitive brain circuits and the spread of tau in vivo in humans.
Phase 2/3Authorised not given A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer’s Disease (DIAD)
Phase 2/3Authorised not given Tau and Amyloid PET imaging in normal aging, early Alzheimer's disease and related syndroms.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow XTR006

Following is part of Solo: you see every change to XTR006 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in